Jefferson scientists identify gene mutation potentially involved in breast cancer initiation(PHILADELPHIA) Researchers at Jefferson Medical College and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia and at the Albert Einstein College of Medicine in New York have found evidence suggesting that a mutation in a gene that normally helps block the formation of breast tumors could play a role in the initiation of a major form of breast cancer.
The team, led by cell biologist Michael P. Lisanti, M.D., Ph.D., professor of cancer biology at Jefferson Medical College and Richard Pestell, M.D., Ph.D., director of Jefferson's Kimmel Cancer Center, found that a known mutation in the Caveolin-1 gene is present in approximately 19 percent of all breast cancers that are fed by estrogen Ė so called "estrogen receptor-positive" cells. The group also discovered six new Caveolin-1 mutations associated with estrogen-driven breast cancers. As many as nearly 35 percent of such breast cancers may carry Caveolin-1 mutations, Dr. Lisanti says. Caveolin proteins, which play important roles in cell communication, are also involved in a number of diseases and conditions, such as cancer, atherosclerosis, diabetes, Alzheimer's disease and muscular dystrophy.
The researchers, reporting in June 2006 in the American Journal of Pathology, say their results open up the possibility that Caveolin-1 mutations may be involved in the development of estrogen-positive human breast cancer, which accounts for some 70 percent of all breast cancers. "This is the first demonstration that a specific Caveolin-1 mutation is exclusively connected to being estrogen-receptor positive," says Dr. Lisanti, noting that in tests of breast tumor samples, none of those that were estrogen-receptor negative showed caveolin mutations.
"One-third of estrogen receptor-positive patients actually had caveolin mutations, making it one of the most common mutations in that population," he says. "Usually about 70 percent of all human breast cancers are estrogen receptor-positive and 30 percent are negative. That's one-third of the major form of human breast cancer."
Dr. Lisanti explains that he and his colleagues had wanted to test the hypothesis that the loss of a functioning Caveolin-1 gene could increase the activity, or "upregulate" the expression of estrogen receptors. Only 5 to 10 percent of the cells in the normal human breast express estrogen receptors, yet the receptor activity for some reason rises dramatically in premalignant lesions and cancer.
Dr. Lisanti's team developed mice lacking the Caveolin-1 gene and found a dramatic increase in both number and activity of estrogen-positive receptors in mouse breast tissue, specifically in breast epithelial cells, in turn, promoting cell growth. Caveolin-1, Dr. Lisanti suggests, could act as a kind of "switch" that regulates receptor activity and cell proliferation.
"It is the first time that we can say that the loss of function of caveolin gene expression plays a role in the specific upregulation of estrogen receptor," he says. "It helps explain the nature of this transition from nonmalignant to malignant tissue."
Dr. Lisanti explains that estrogen receptors are thought to help turn on certain genes such as cyclin D1, which in turn promote cancer development. "We've elicited a new pathway for mammary tumorigenesis," he says. "Before, we could say that estrogen receptors turned on cyclin D1, which was enough to cause mammary tumorigenesis. Now we've added another link: inactivation of caveolin as the first initiation step."
The team found that cyclin D1 activity in human breast cancer samples was increased, specifically after estrogen treatment. "In essence, we have created a preclinical model in which to study the role of estrogen and caveolin deficiency in breast cancer development," he says. "It's a new signaling pathway for understanding the pathogenesis of human breast cancer with caveolin gene inactivation as the initiating step. It all fits together."
The group subsequently showed in laboratory studies that in mouse mammary cells lacking caveolin and certain growth-stimulating factors, estrogen receptors were again increased, leading them to conclude that two factors may be required for estrogen receptor upregulation: Caveolin gene inactivation and growth factor depletion.
The findings may have clinical implications. According to Dr. Lisanti, those breast cancer patients who are estrogen receptor-positive and who have caveolin mutations are much more likely to have a cancer recur than are such individuals who don't carry caveolin gene mutations. "It's a risk factor," he notes.
Last reviewed: By John M. Grohol, Psy.D. on 30 Apr 2016
Published on PsychCentral.com. All rights reserved.